Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Yuanyuan Zhang, Yanyan Zhong, Lin Pan, Jing Dong
Abstract
The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of "cytokine storm" in COVID-19. However, we still lack reliable studies to verify "cytokine storm" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated.
Topics & Concepts
Cytokine stormTocilizumabARDSCoronavirus disease 2019 (COVID-19)Cytokine release syndromeMedicinePneumoniaPandemicCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCytokineInterleukin 6Viral pneumoniaVirologyImmunologyDiseaseInfectious disease (medical specialty)LungInternal medicineOutbreakRheumatoid arthritisCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research